{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:49:59Z","timestamp":1792457399129,"version":"4.5.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>There is a lack of data regarding suitable dosage when administering intravenous ganciclovir (GCV) or oral valganciclovir (valGCV) to preterm and low birthweight infants with cytomegalovirus (CMV) disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data were collected for infants born before 32 weeks gestation and\/or weighing less than 1.8\u2009kg treated for CMV disease with GCV or valGCV between 2016 and 2023.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Twenty-four infants (58% males and 48% Asian ethnicity) with a median gestation of 31 weeks [interquartile range (IQR): 26.6\u201336.1], median weight of 950\u2009g (IQR: 470\u20131692) and median age of 45 days (IQR: 6\u201384) at initiation of treatment were included. Seventeen infants were treated for symptomatic postnatal CMV and 7 for symptomatic congenital CMV. Most infants receiving GCV had 6\u2009mg\/kg twice daily dosing and most receiving valGCV had 16\u2009mg\/kg twice daily dosing. Fourteen infants had drug concentrations measured with combined geometric mean minimum blood plasma concentration (C<jats:sub>min<\/jats:sub>) of 2.44\u2009mg\/L and maximum blood plasma concentration of 7.98\u2009mg\/L for doses of 6\u2009mg\/kg GCV and 16\u2009mg\/kg valGCV, which is higher compared with term infants. The estimated area under the curve at 12 hours (AUC<jats:sub>0\u201312h<\/jats:sub>) was 54.34\u2009mg \u00d7 h\/L, which doubled the value for term infants in a previous study. Notably, AUC<jats:sub>0\u201312h<\/jats:sub> had an inverse relationship with gestational age and weight. Infants with lower gestation and higher C<jats:sub>min<\/jats:sub> showed a higher tendency for more than 1 adverse effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>GCV and valGCV use among preterm and very low birthweight infants with CMV disease resulted in a higher incidence of adverse events, increased AUC<jats:sub>0\u201312h<\/jats:sub> and elevated C<jats:sub>min<\/jats:sub> compared with term infants. Further pharmacokinetic studies are necessary to determine the ideal dosage in this population.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004605","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T18:01:35Z","timestamp":1731520895000},"page":"319-325","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Dosing, Toxicity and Drug Concentrations for Ganciclovir\/Valganciclovir in Preterm and Low Birthweight Infants Treated for Cytomegalovirus"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6138-1077","authenticated-orcid":false,"given":"Asrar","family":"Abu Bakar","sequence":"first","affiliation":[{"name":"Department of Paediatrics, International Islamic University Malaysia, Kuantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Payne","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Tickner","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5259-6289","authenticated-orcid":false,"given":"Muhd Alwi","family":"Muhd Helmi","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, International Islamic University Malaysia, Kuantan, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5738-5528","authenticated-orcid":false,"given":"Tom G.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen"},{"name":"Department of Pharmacy, Tergooi Medical Center, Hilversum, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermione","family":"Lyall","sequence":"additional","affiliation":[{"name":"Department of Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1097\/INF.0000000000001763","article-title":"Congenital cytomegalovirus: a European expert consensus statement on diagnosis and management.","volume":"36","author":"Luck","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"e2120736","DOI":"10.1001\/jamanetworkopen.2021.20736","article-title":"Congenital cytomegalovirus infection burden and epidemiologic risk factors in countries with universal screening: a systematic review and meta-analysis.","volume":"4","author":"Ssentongo","year":"2021","journal-title":"JAMA Netw Open"},{"key":"R3-20250609","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.earlhumdev.2011.08.021","article-title":"Evidence based management guidelines for the detection and treatment of congenital CMV.","volume":"87","author":"Kadambari","year":"2011","journal-title":"Early Hum Dev"},{"key":"R4-20250609","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/uog.23143","article-title":"Outcome of fetuses with congenital cytomegalovirus infection and normal ultrasound at diagnosis: systematic review and meta-analysis.","volume":"57","author":"Buca","year":"2021","journal-title":"Ultrasound Obstet Gynecol"},{"key":"R5-20250609","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection.","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev Med Virol"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1542\/peds.2014-1173","article-title":"Hearing loss and congenital CMV infection: a systematic review.","volume":"134","author":"Goderis","year":"2014","journal-title":"Pediatrics"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1001\/jamapediatrics.2019.4532","article-title":"Association of adverse hearing, growth, and discharge age outcomes with postnatal cytomegalovirus infection in infants with very low birth weight.","volume":"174","author":"Weimer","year":"2020","journal-title":"JAMA Pediatr"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jiy695","article-title":"Blood viral load in symptomatic congenital cytomegalovirus infection.","volume":"219","author":"Marsico","year":"2019","journal-title":"J Infect Dis"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1542\/peds.2013-2217","article-title":"Incidence and impact of CMV infection in very low birth weight infants.","volume":"133","author":"Turner","year":"2014","journal-title":"Pediatrics"},{"key":"R10-20250609","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3390\/v13101897","article-title":"Clinical, virologic and immunologic correlates of breast milk acquired cytomegalovirus (CMV) infections in very low birth weight (VLBW) infants in a newborn intensive care unit (NICU) setting.","volume":"13","author":"Hernandez-Alvarado","year":"2021","journal-title":"Viruses"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"e20170635","DOI":"10.1542\/peds.2017-0635","article-title":"Outcome of preterm infants with postnatal cytomegalovirus infection.","volume":"141","author":"Gunkel","year":"2018","journal-title":"Pediatrics"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1136\/adc.62.8.780","article-title":"Early acquisition of cytomegalovirus infection.","volume":"62","author":"Peckham","year":"1987","journal-title":"Arch Dis Child"},{"key":"R13-20250609","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/archdischild-2019-317650","article-title":"Postnatally acquired cytomegalovirus infection in extremely premature infants: how best to manage?","volume":"105","author":"Kadambari","year":"2020","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s40746-022-00261-y","article-title":"Perinatal cytomegalovirus infection.","volume":"8","author":"Carmona","year":"2022","journal-title":"Curr Treat Options Peds"},{"key":"R15-20250609","first-page":"1085","article-title":"Clinical pharmacology of ganciclovir and valganciclovir in infants and children.","volume":"8","author":"Pacifici","year":"2021","journal-title":"J Drug Des Res"},{"key":"R16-20250609","doi-asserted-by":"crossref","first-page":"455","DOI":"10.2165\/00003495-199448030-00009","article-title":"Ganciclovir. An update of its therapeutic use in cytomegalovirus infection.","volume":"48","author":"Markham","year":"1994","journal-title":"Drugs"},{"key":"R17-20250609","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1600-6143.2010.03112.x","article-title":"Valganciclovir: recent progress.","volume":"10","author":"Pescovitz","year":"2010","journal-title":"Am J Transplant"},{"key":"R18-20250609","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/jpids\/piac034","article-title":"Ganciclovir and valganciclovir use among infants with congenital cytomegalovirus: data from a multicenter electronic health record dataset in the United States.","volume":"11","author":"Leung","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R19-20250609","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1056\/NEJMoa1404599","article-title":"Valganciclovir for symptomatic congenital cytomegalovirus disease.","volume":"372","author":"Kimberlin","year":"2015","journal-title":"N Engl J Med"},{"key":"R20-20250609","doi-asserted-by":"crossref","first-page":"18","DOI":"10.24018\/clinicmed.2022.3.1.122","article-title":"Efficacy and tolerability of valganciclovir 6 months vs 6 weeks in symptomatic cytomegalovirus infection in infants: an open level randomized controlled trial.","volume":"3","author":"Ruby","year":"2022","journal-title":"Eur J Transl Clin Med"},{"key":"R21-20250609","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1128\/AAC.06423-11","article-title":"A pharmacodynamic model of ganciclovir antiviral effect and toxicity for lymphoblastoid cells suggests a new dosing regimen to treat cytomegalovirus infection.","volume":"56","author":"Janoly-Dumenil","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"R22-20250609","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1086\/528376","article-title":"Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease.","volume":"197","author":"Kimberlin","year":"2008","journal-title":"J Infect Dis"},{"key":"R23-20250609","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/sj.clpt.6100150","article-title":"Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.","volume":"81","author":"Acosta","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"R24-20250609","doi-asserted-by":"crossref","first-page":"e02254","DOI":"10.1128\/AAC.02254-20","article-title":"Population pharmacokinetics of intravenous ganciclovir and oral valganciclovir in a pediatric population to optimize dosing regimens.","volume":"65","author":"Nguyen","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250609","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3390\/microorganisms8101516","article-title":"Congenital cytomegalovirus infection: update on diagnosis and treatment.","volume":"8","author":"Chiopris","year":"2020","journal-title":"Microorganisms"},{"key":"R26-20250609","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/sj.jp.7211854","article-title":"Oral valganciclovir for symptomatic congenital cytomegalovirus infection in an extremely low birth weight infant.","volume":"28","author":"Muller","year":"2008","journal-title":"J Perinatol"},{"key":"R27-20250609","first-page":"93","article-title":"Treatment of congenital cytomegalovirus and ganciclovir therapeutic drug monitoring in twin preterm infants.","volume":"28","author":"Pich\u00e9-Renaud","year":"2023","journal-title":"The J Pediatr Pharmacol Ther"},{"key":"R28-20250609","article-title":"NHS England maternity statistics.","author":"Sharon"},{"key":"R29-20250609","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic drug monitoring of ganciclovir: where are we?","volume":"44","author":"M\u00e4rtson","year":"2022","journal-title":"Ther Drug Monit"},{"key":"R30-20250609","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/INF.0000000000003995","article-title":"Discrepancies in management of congenital cytomegalovirus in preterm infants: an international survey.","volume":"42","author":"Petrunin","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R31-20250609","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17425255.2015.988139","article-title":"Clinical pharmacokinetics and pharmacodynamics of ganciclovir and valganciclovir in children with cytomegalovirus infection.","volume":"11","author":"Stockmann","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"R32-20250609","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/clpt.1993.4","article-title":"Single-dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections. NIAID Collaborative Antiviral Study Group.","volume":"53","author":"Trang","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"R33-20250609","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ijantimicag.2010.11.033","article-title":"Ganciclovir treatment in children: evidence of subtherapeutic levels.","volume":"37","author":"Luck","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"R34-20250609","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1093\/clinids\/10.Supplement_3.S507","article-title":"Clinical pharmacokinetics of ganciclovir in patients with normal and impaired renal function.","volume":"10","author":"Sommadossi","year":"1988","journal-title":"Rev Infect Dis"},{"key":"R35-20250609","first-page":"424","article-title":"Glomerular filtration rate estimation formulas for pediatric and neonatal Use.","volume":"23","author":"Muhari-Stark","year":"2018","journal-title":"J Pediatr Pharmacol Ther"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:00:24Z","timestamp":1749502824000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004605","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}